📊 ALT Key Takeaways
Is Altimmune, Inc. (ALT) a Good Investment?
Altimmune is a pre-revenue stage biopharmaceutical company with severe financial distress, burning $67.5M in annual operating cash flow against only $43.8M in cash reserves. The company generated minimal revenue ($41K) with catastrophic operating losses of $94.5M, indicating no viable commercialized products and unsustainable cash burn rate that threatens near-term viability. Without significant funding or breakthrough clinical results, the company faces acute liquidity risk within 12 months.
Altimmune’s fundamentals reflect a clinical-stage biotech with negligible revenue, deeply negative margins, and substantial operating and free cash flow burn, so the business is not yet financially self-sustaining. The balance sheet is currently a relative strength, with high liquidity, modest leverage, and meaningful equity, but the present cash position appears light versus the annual burn rate. Growth quality is weak because the reported revenue increase is from a very small base and does not offset persistent losses.
Why Buy Altimmune, Inc. Stock? ALT Key Strengths
- Strong balance sheet structure with low debt-to-equity ratio of 0.15x limiting leverage risk
- Adequate equity cushion of $224.9M providing some runway for operations
- High liquidity ratios (18.55x current ratio) for near-term obligation coverage
- Strong near-term liquidity with current and quick ratios of 18.55x
- Low leverage with debt/equity of 0.15x and substantial equity of $224.89M
- Asset base remains solid relative to liabilities, supporting financial flexibility
ALT Stock Risks: Altimmune, Inc. Investment Risks
- Catastrophic cash burn of $67.5M annually with only $43.8M cash on hand creates imminent liquidity crisis
- Virtually no revenue generation ($41K) indicates no commercialized products or market traction
- Operating losses of $94.5M with negative operating margin of -230,461% demonstrate fundamental unprofitability
- Extremely weak profitability with operating loss of $94.49M and net loss of $88.09M
- Cash burn is high, with operating cash flow of -$67.53M and free cash flow of -$67.55M
- Revenue base is immaterial at $41K, making growth quality poor and increasing dependence on external funding
Key Metrics to Watch
- Monthly cash burn rate and cash runway duration
- Clinical trial progress and FDA approval milestones
- Quarterly revenue growth from potential product launches
- Cash runway versus operating cash burn
- Progression of R&D-driven losses relative to any meaningful revenue generation
Altimmune, Inc. (ALT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 18.55x current ratio provides a solid financial cushion.
ALT Profit Margin, ROE & Profitability Analysis
ALT vs Healthcare Sector: How Altimmune, Inc. Compares
How Altimmune, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Altimmune, Inc. Stock Overvalued? ALT Valuation Analysis 2026
Based on fundamental analysis, Altimmune, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Altimmune, Inc. Balance Sheet: ALT Debt, Cash & Liquidity
ALT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Altimmune, Inc.'s revenue has declined by 24% over the 5-year period, indicating business contraction. The most recent EPS of $-1.34 indicates the company is currently unprofitable.
ALT Revenue Growth, EPS Growth & YoY Performance
ALT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $5.0K | -$19.0M | $-0.21 |
| Q2 2025 | $5.0K | -$19.6M | $-0.27 |
| Q1 2025 | $5.0K | -$19.6M | $-0.26 |
| Q3 2024 | $5.0K | -$16.1M | $-0.32 |
| Q2 2024 | $5.0K | -$16.1M | $-0.32 |
| Q1 2024 | $5.0K | -$20.1M | $-0.34 |
| Q3 2023 | $2.0K | -$16.1M | $-0.39 |
| Q2 2023 | $6.0K | -$16.1M | $-0.32 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Altimmune, Inc. Dividends, Buybacks & Capital Allocation
ALT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Altimmune, Inc. (CIK: 0001326190)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 6, 2026 | 4 | xslF345X06/form4-04062026_040403.xml | View → |
| Apr 1, 2026 | 4 | xslF345X06/form4-04012026_040406.xml | View → |
| Apr 1, 2026 | 4 | xslF345X06/form4-04012026_040404.xml | View → |
| Mar 17, 2026 | DEF 14A | alt-20260416xdef14a.htm | View → |
| Mar 9, 2026 | 4 | xslF345X05/form4-03092026_070301.xml | View → |
❓ Frequently Asked Questions about ALT
What is the AI rating for ALT?
Altimmune, Inc. (ALT) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ALT's key strengths?
Claude: Strong balance sheet structure with low debt-to-equity ratio of 0.15x limiting leverage risk. Adequate equity cushion of $224.9M providing some runway for operations. ChatGPT: Strong near-term liquidity with current and quick ratios of 18.55x. Low leverage with debt/equity of 0.15x and substantial equity of $224.89M.
What are the risks of investing in ALT?
Claude: Catastrophic cash burn of $67.5M annually with only $43.8M cash on hand creates imminent liquidity crisis. Virtually no revenue generation ($41K) indicates no commercialized products or market traction. ChatGPT: Extremely weak profitability with operating loss of $94.49M and net loss of $88.09M. Cash burn is high, with operating cash flow of -$67.53M and free cash flow of -$67.55M.
What is ALT's revenue and growth?
Altimmune, Inc. reported revenue of $41.0K.
Does ALT pay dividends?
Altimmune, Inc. pays dividends, with $200.3M distributed to shareholders in the trailing twelve months.
Where can I find ALT SEC filings?
Official SEC filings for Altimmune, Inc. (CIK: 0001326190) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ALT's EPS?
Altimmune, Inc. has a diluted EPS of $-1.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ALT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Altimmune, Inc. has a SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ALT stock overvalued or undervalued?
Valuation metrics for ALT: ROE of -39.2% (sector avg: 15%), net margin of -214,861.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ALT stock in 2026?
Our dual AI analysis gives Altimmune, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ALT's free cash flow?
Altimmune, Inc.'s operating cash flow is $-67.5M, with capital expenditures of $11.0K. FCF margin is -164,746.3%.
How does ALT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -214,861.0% (avg: 12%), ROE -39.2% (avg: 15%), current ratio 18.55 (avg: 2).